



## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

## ELI LILLY AND COMPANY

By Lindam. Durbin

Pate January 18, 2005

## REISSUE PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Harlan Edgar Shannon et al.	) Confirmation No. 9165
Serial No.:	09/935,513	ý
Filed:	August 22, 2001	) Group Art Unit: ) 1617
For:	Method for Treating Pain	) Examiner: ) Theodore J. Criares
Docket No.:	X-10576A	)

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit a copy of each of the documents listed on the attached Form PTO-1449 (modified) for consideration by the Examiner.

Since this Statement is being filed after the period specified in §1.97(b), but before the mailing date of a final action or a notice of allowance, please charge the amount of \$180.00, the fee under 37 C.F.R. 1.17(p), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

01/25/2005 GWDRDDF1 00000036 050840 09935513

01 FC:1806

180.00 DA

Applicants request consideration of this information.

Respectfully submitted,

Nelsen L. Lentz

Attorney for Applicants Registration No. 38,537

Phone: 317-276-1207

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

January 17, 2005

\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			Sheet 1 of 1		
FORM PTO 1449 Checking	Atty. Docket No. X-10576A	Serial No 09/935/513			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Harlan Edgar Shannon et al.				
	Filing Date August 22, 2001	Group 1617			

		U	.S. PATENT D	OCUMEN	NTS			<del>-</del>	
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code <sup>2</sup> (if know	Publication Date vn) MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear		
1	AA	US							
	AB	US							
	AC	US							
	AD	US							
		FOR	EIGN PATENT	T DOCUM	1ENT	S			
Examiner Initials*	Cite	Foreign Patent Document		Name of P				T <sup>6</sup>	
	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code5 (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document		Pages, Columns, Lines, Whe Relevant Passages or Releva Figures Appear		;   '	
	BA								
	BB		1						
,	BC								
		NON P	ATENT LITERAT	URE DOC	UMEN	TS .		<u> </u>	
Examiner	Cite			TAL LETTERS), title of the article (when appropriate), title of the item 76					
Initials*	No. 1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.							
	CM	VAISHALI P. BAKSHI ET AL., Antagonism of phencyclidine-induced deficits in							
		prepulse inhibition by the putative atypical antipsychotic olanzapine,							
	CN	Psychopharmacology 1995, 198-201, Vol. 122  RAY W. FULLER ET AL., Neuroendocrine evidence for antagonism of serotonin and							
		dopamine receptors by							
	-	Research Communications in Chemical Pathology and Pharmacology, July 1992, 87-							
	1	93, Vol. 77, No. 1	93, Vol. 77, No. 1						
	CO		NICHOLAS A. MOORE ET AL., The Behavioral Pharmacology of Olanzapine, a						
		Novel "Atypical" Antipsychotic Agent, The Journal of Pharmacology and Experimental Therapeutics, 1992, 545-551, Vol. 262, No. 2							
	СР	FRANK P. BYMASTER ET AL., Radioreceptor Binding Profile of the Atypical							
		Antipsychotic Olanzapine, Neuropsychopharmacology, 1996, 87-96, Vol. 14, No. 2							
	CQ	SHELDON H. PRESKORN, MD ET AL., Polypharmacy: When Is It Rational?, Journal of Practical Psychiatry and Behavioral Health, July 1995, 92-98						.*	
Examiner	<del> </del>			Date Consi		· .		<u>.</u>	
Signature					- 1		•		

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.